Platelet activation is crucial for wound healing at sites of endothelial cell injury and involves multiple factors that mediate platelet recruitment, adherence, and aggregation. Platelet activation in response to atherosclerotic plaque rupture or endothelial cell detachment can result in pathologic thrombus formation and acute ischemic events. Current oral antiplatelet agents, aspirin and adenosine diphosphate (ADP) receptor antagonists, are effective but associated with bleeding as they target activation pathways critical for protective hemostasis and pathologic thrombosis. Each inhibits a single platelet activation pathway and does not impact activation by thrombin. The lack of complete inhibition of platelet function allows continued thrombus formation and recurrent thrombotic events. Inhibition of the protease-activated receptor 1 (PAR-1) stimulated by thrombin offers a rational strategy to achieve more comprehensive platelet inhibition when used in combination with standard-of-care, dual antiplatelet therapy. We expect that this new approach may mitigate bleeding risk, because PAR-1 is not essential for hemostasis.
Introduction
Platelets play a crucial role in hemostasis, thrombosis, and inflammation. Their principal function is to prevent the blood loss that follows vessel damage by forming a hemostatic plug at sites of injury. The activation of circulating platelets is critical for this process. However, unwarranted platelet activation results in pathological thrombosis, resulting in acute clinical manifestations of atherothrombotic disease, such as acute coronary syndromes (ACS) or ischemic stroke. Although current antiplatelet agents such as aspirin and adenosine diphosphate (ADP) receptor antagonists have shown clear clinical benefits, they are associated with several clinically important limitations. These include bleeding risk, interindividual variability in platelet responsiveness to therapy, and residual risk of thrombotic events. Other platelet activation pathways, such as the protease-activated receptor 1 (PAR-1) pathway for thrombin, remain functional in the presence of current agents, contributing to the risk of thrombosis and recurrent clinical events. This article will review the role of platelets in hemostasis, thrombosis, and inflammation, including the contributions of various platelet activation pathways. Clinical implications for the use of antiplatelet agents in the treatment of atherothrombotic disease will also be discussed.
Overview of the Role of Platelets in Hemostasis and Thrombosis
Platelet plug formation at sites of vascular injury occurs in 3 stages: initiation, extension, and propagation. 1, 2 Circulating platelets are quiescent under normal circumstances and do not bind to the intact endothelium. However, endothelial damage following injury leads to the exposure of circulating platelets to the subendothelial extracellular matrix (ECM) and triggers platelet recruitment and adhesion. 3 von Willebrand factor (vWF) is a key mediator of platelet adhesion. 4 The interaction between vWF and the platelet receptor glycoprotein (GP) Ib plays an important role in tethering flowing platelets to the subendothelium at sites of injury under conditions of high shear such as are found in small arteries, arterioles, and stenosed arteries. 5 GP VI is the major platelet collagen receptor that enhances platelet adhesion to collagen under low shear; integrin a 2 b 1 (GP Ia/IIa) contributes to adhesion but appears to have a limited role in platelet activation. 3, [5] [6] [7] GP VI is required for collagen-mediated activation and spreading of platelets on the matrix protein. 8 The initiation phase culminates in adherence of a platelet monolayer to the ECM via direct and indirect interactions between high-affinity platelet integrins and collagen.
In the extension phase, additional platelets are recruited and activated via soluble agonists. These include ADP, thromboxane A 2 (TxA 2 ), epinephrine, serotonin, and thrombin. 1,9 ADP and TxA 2 are secreted from adherent platelets and promote alterations in platelet shape and granule secretion. Platelet activation is thus amplified and sustained during this phase. Very low concentrations of thrombin are required to activate platelets, and therefore thrombin is considered one of the most potent platelet activators. [10] [11] [12] Thrombin facilitates the production of fibrin from fibrinogen, contributing to the formation and stabilization of the hemostatic plug. 1 Fibrinogen bridges stabilize the thrombus. 13, 14 The primary platelet integrin for aggregation, GP IIb/IIIa, 15 is activated through the concerted actions of soluble agonists. GP IIb/IIIa is the most abundant platelet GP and facilitates plateletÀplatelet interactions via fibrinogen and vWF bridges, which result in the growth and stabilization of the hemostatic plug. 14, 15 In the final propagation phase, the platelet-rich thrombus and coagulation cascades reinforce one another and culminate in the generation of a stable plateletfibrin-rich plug at sites of injury.
Inappropriate platelet activation can lead to pathological thrombosis. 16 The most common triggers are the disruption of an atherosclerotic plaque and detachment of endothelial cells, which expose circulating platelets to a highly thrombogenic environment and result in uncontrolled platelet activation. This leads to the formation of platelet-rich thrombi that occlude the arterial lumen, impairing blood flow and oxygen supply, and resulting in acute events. 17, 18 In non-ST-segment elevation (NSTE) ACS, thrombi are typically not completely occlusive and are primarily composed of platelets. [19] [20] [21] In ST-segment elevation (STE) myocardial infarction (MI), the thrombus usually completely occludes blood flow and contains, in addition to the platelet-rich core, a superimposed fibrin mesh generated by the coagulation cascade. [19] [20] [21] Biomarkers such as vWF and plasminogen activator inhibitor-1 (PAI-1) have been associated with worse prognosis in both NSTE ACS and STE MI.
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Platelet Activation Pathways
Platelets can be activated by multiple factors ( Figure 1) ; the key ones include ADP, TxA 2 , collagen, and thrombin. 2 Signaling via ADP receptors contributes to platelet activation during both protective hemostasis and pathological thrombosis. ADP released from the granules of adherent platelets activates platelets by binding to platelet ADP receptors, P 2 Y 1 and P 2 Y 12 , and contributes to platelet recruitment into stable hemostatic plugs. ADP also contributes to platelet activation during pathological thrombosis. ADP signaling from the P 2 Y 1 receptor induces platelet shape change and rapid transient aggregation, 26 whereas signaling from the P 2 Y 12 receptor facilitates sustained irreversible aggregation 27 and stimulates surface expression of proinflammatory P-selectin and secretion of TxA 2 . 28 These actions collectively contribute to thrombus growth and stability. 29 TxA 2 is produced de novo and, like ADP, is released from adherent platelets and positively reinforces platelet activation, contributing to both hemostatic plug formation and pathological thrombosis. It is generated from arachidonic acid through conversion by cyclooxygenase 1 (COX-1) and Tx synthase. 9 TxA 2 binds platelet receptors TPa and TPb; however, its effects in platelets are mediated primarily through TPa. 30 The concentration of TxA 2 and prostacyclin is increased in patients with unstable angina or following acute MI, 31 indicating a role for TxA 2 -mediated platelet activation during pathological thrombosis.
Subendothelial fibrillar collagen is a strong thrombogenic substrate. Binding of collagen to GP VI alters platelet integrins to a high-affinity state and induces the release of ADP and TxA 2 .
3 Stimulation of platelets as a result of adhesion leads to spreading, further activation of GP IIb/IIIa and binding to soluble fibrinogen, and granule secretion. 32 Fibrillar collagen stimulates strong and prolonged calcium release, which induces the procoagulant activity of platelets. 9 Platelet interaction with collagen is thus critical for hemostasis and thrombosis.
Thrombin is considered one of the most potent platelet activators, 10 as indicated by the fact that it promotes activation at extremely low concentrations (lower than those required for coagulation). 11, 12 Human platelets express two PARs for thrombin (PAR-1 and PAR-4), with PAR-1 being the principal receptor activated at low thrombin concentrations (PAR-4 is activated at higher thrombin concentrations). 1, 33 Thrombin activates platelets by binding the extracellular N-terminus of PAR-1 and cleaving the receptor to expose a new extracellular N-terminus, which functions as a tethered ligand to initiate PAR-1 signaling ( Figure 2 ). 34 Activation of the PAR-1 pathway promotes multiple prothrombotic functions, including platelet procoagulant activity, shape change, secretion of platelet agonists (ADP and TxA 2 ), expression of proinflammatory P-selectin, activation of GP IIb/IIIa receptor, and platelet aggregation. [35] [36] [37] [38] The PAR-1 pathway is an important contributor to pathological thrombosis but may not be required for protective hemostasis, as suggested by several preclinical studies. [39] [40] [41] First, in a guinea pig model of arterial thrombosis, the nonpeptide PAR-1 antagonist (FR171113) inhibited occlusive thrombus formation in a dose-dependent manner without prolonging the bleeding time. 40 In addition, pretreatment with FR171113 did not significantly alter activated partial thromboplastin time, prothrombin time, or thrombin time at the dosage where the drug showed significant antithrombotic effects, suggesting that PAR-1 inhibition does not affect the coagulation cascade. 40 Conversely, pretreatment with the direct thrombin inhibitor argatroban inhibited thrombus formation but also resulted in prolonged bleeding times that were dose-dependent. 40 Moreover, PAR-1 inhibition with FR171113 did not inhibit the ADP-or collagen-induced aggregation of platelets in vitro, suggesting that PAR-1 inhibition may not affect platelet activation pathways involved in protective hemostasis. 40 Second, inhibition of PAR-1 activity with the selective, small-molecule antagonist RWJ-58259 significantly delayed or prevented arterial thrombosis in cynomolgus monkeys with minimal effect on platelet-dependent hematological and coagulation functions. 39 The primary receptor for thrombin in mice is PAR-4, and it is analogous to PAR-1 in humans. 10 In response to experimentally induced arteriolar injury, genetic inactivation of PAR-4 in mice (Par4À/À) did not interfere with the initial deposition of platelets or fibrin, which is required for normal healing, but did prevent the growth of platelet thrombus into the lumen. 41 Par4À/À mice, however, show no spontaneous bleeding, suggesting that the PAR-4 pathway is required for thrombus formation but not for hemostasis. 41 Finally, thrombinmediated cleavage of fibrinogen into fibrin is more important for hemostasis than thrombin-mediated platelet activation as fibrinogen knockout mice (FibÀ/À) exhibit a more severe bleeding phenotype compared with Par4À/À knockout mice, which have a relatively mild bleeding defect. 10, 42, 43 Platelets and Inflammation
The participation of platelets in inflammatory processes represents another important attribute of platelet function. Platelets interact with the vascular endothelium and link inflammation, thrombosis, and atherogenesis. 44, 45 vWF from endothelial cells recruits platelets in response to inflammatory signals and promotes platelet adhesion to the endothelium. P-selectin, which is present on both platelets and endothelial cells, mediates initial ''loose'' contact between platelets and the endothelium and platelet rolling via binding to GP Ib, whereas firm adhesion is mediated by GP IIb/IIIa and a V b 3 via fibrinogen. 44 Adherent platelets become activated and secrete multiple inflammatory mediators. For example, the release of CD40 ligand promotes endothelial inflammation via production or recruitment of reactive oxygen species (ROS), adhesion molecules, chemokines, and tissue factor. 46, 47 In addition, secretion of ROS enhances ADP-dependent platelet recruitment to a growing thrombus. 48 Platelets release multiple chemokines upon activation, including Regulated on Activation Normal T Cell Expressed and Secreted/Chemokine (c-c motif) ligand 5 (RANTES/CCL5) and platelet factor 4 Chemokine (c-x-c motif) ligand 4 (PF4 or CXCL4). 49 RANTES/CCL5 becomes deposited on inflamed or atherosclerotic endothelium and increases the local recruitment of monocytes; 50 heterodimers formed by RANTES/CCL5 and PF4 further amplify monocyte adhesion induced by RANTES. 50, 51 The activation of inflammatory cascades results in the recruitment of immune cells. Leukocytes, including both monocytes and neutrophils, tether to adherent platelets via interaction between P-selectin glycoprotein ligand 1 (PSGL-1) on leukocytes and platelet P-selectin ( Figure 1) . 52 Firm adhesion requires binding of macrophage 1 antigen (Mac-1) on leukocytes to GP Iba and other platelet receptors. 53 These interactions promote activation of inflammatory cascades in monocytes and leukocyte adhesion, resulting in the infiltration of inflammatory cells into the vessel wall.
Overview of Antiplatelet Therapy
Aspirin (acetylsalicylic acid) is the most widely used antiplatelet agent for treatment of atherothrombotic disease. Aspirin irreversibly blocks COX-1, which is required for TxA 2 production, 54, 55 and thereby reduces platelet activation stimulated by TxA 2 . Clinical investigations with aspirin monotherapy have consistently documented the benefit of aspirin in ACS, 56, 57 percutaneous coronary intervention (PCI), 58, 59 primary prevention, 60 and secondary prevention. 56 irreversibly inhibit the P 2 Y 12 receptor. Antiplatelet therapy with aspirin and ticlopidine was shown to be superior to treatment with aspirin and phenprocoumon (a coumarin derivative) after intracoronary stent placement. 62 In addition, the STARS study demonstrated a significant reduction in the rate of stent thrombosis for patients randomized to aspirin plus ticlopidine (0.5%), compared with aspirin plus warfarin (2.7%) or aspirin monotherapy (3.6%; P ¼ .005). 63 Clopidogrel has provided clinical benefits as single antiplatelet therapy (the CAPRIE trial) 64 and as an add-on to aspirin in participants with established vascular disease (CHARISMA), 65, 66 in patients with NSTE ACS (CURE), 67 and in patients following PCI (PCI-CURE, CREDO; Table 1) . 68, 69 The benefit of clopidogrel added on to aspirin or to aspirin and standard fibrinolytic regimen was shown in patients with STE MI (COMMIT 70 and CLARITY; Table 1   71 ). The relatively slow onset of action and limited potency of clopidogrel at its approved regimen has stimulated a number of studies evaluating higher doses of clopidogrel that can act more rapidly and be more effective in antagonizing P 2 Y 12 receptor function. [75] [76] [77] [78] [79] [80] [81] [82] Most recently, the CURRENT-OASIS 7 trial evaluated the efficacy and safety of double-dose versus standard-dose clopidogrel in patients with ACS (Table 1) . 72 There was no significant difference in the primary end point (composite of cardiovascular death, MI, or stroke) at 30 days between patients receiving double-dose versus standard-dose clopidogrel (Table 1) . 72 However, in patients who underwent PCI (n ¼ 17 232), double-dose clopidogrel was associated with a significant 15% relative reduction in the primary end point and a 42% relative reduction in definite stent thrombosis versus the standard-dose regimen. 72 There was a modest excess in CURRENT-defined major bleeds but no difference in Thrombolysis in Myocardial Infarction (TIMI) major bleeds, intracranial hemorrhage, fatal bleeds, or coronary artery bypass graft-related bleeds between the double-dose and standarddose clopidogrel treatment arms. Prasugrel, a more potent P 2 Y 12 antagonist with a faster onset of action, was approved in 2009 in both the United States and Europe. Prasugrel demonstrated superior efficacy over clopidogrel in reducing thrombotic events in patients with ACS scheduled to undergo PCI in the TRITON trial (Table 1) . 73 However, this benefit was offset by significantly increased risk of major bleeding, life-threatening bleeding, and nonfatal bleeding, and significantly increased need for transfusions. 73 Post hoc analyses revealed that patients with stroke or transient ischemic attack (TIA) had a net clinical harm from prasugrel, whereas patients !75 years of age and those weighing <60 kg experienced no net benefit from aspirin plus prasugrel. 73 In patients with STEMI, however, therapy with aspirin plus prasugrel was associated with a significant net clinical benefit, without excess bleeding risk. 83 Net benefit from prasugrel was also observed in patients with diabetes 84 and in patients receiving at least 1 stent. 85 Ticagrelor (AZD 6140) is a novel nonthienopyridine, directacting, oral inhibitor of the P 2 Y 12 ADP receptor characterized by a rapid onset of action (2 hours to peak platelet inhibition) and a relatively rapid (12 hours) reversal of platelet inhibition. 86 Ticagrelor has demonstrated greater potency and consistency of platelet inhibition compared with clopidogrel. 87 The efficacy and safety of ticagrelor plus aspirin versus clopidogrel plus aspirin were evaluated in the phase 3 PLATO trial in patients with ACS, with or without STE ( Table 1) . 74 Treatment with ticagrelor led to a significant reduction in the incidence of the composite end point of death from vascular causes, MI, or stroke versus clopidogrel (9.8% vs 11.7%, P < .001) as well as a significant reduction in mortality from any cause (4.5% vs 5.9%, P < .001) after 1 year. 74 No significant differences in the rates of major bleeding were observed between the treatment arms. Ticagrelor was associated with higher rates of other adverse events versus clopidogrel, including dyspnea (13.8% vs 7.8%, P < .001), syncope (1.1% vs 0.8%, P ¼ .8), increase in serum uric acid from baseline (15% vs 7%, P < .001), and increase in serum creatinine from baseline (11% vs 9%, P < .001). 74 Phase 3 trials with another novel, intravenous P 2 Y 12 ADP receptor antagonist, cangrelor, have been terminated due to lack of efficacy versus clopidogrel in interim data analyses.
Available GP IIb/IIIa inhibitors include eptifibatide, tirofiban, and abciximab. Eptifibatide and tirofiban are competitive inhibitors, whereas abciximab binds strongly to the GP IIb/IIIa receptor with a slow off-rate. 55 A meta-analysis of 6 trials evaluating GP IIb/IIIa inhibition for NSTE ACS in 31 402 patients treated with aspirin and heparin demonstrated a relative 9% reduction in the combined rate of death or MI at 30 days with GP IIb/IIIa inhibitors versus placebo or control (10.8% vs 11.8%, P ¼ .015). 88 The absolute treatment benefit was greatest in high-risk patients. Of note, compared with those receiving control, women receiving GP IIb/IIIa inhibitors experienced significantly higher rates of death (3.9% vs 3.6%, P ¼ .03) and death/MI (11.5% vs 10.4%, P ¼ .0001), resulting in a net increased risk of death with GP IIb/IIIa inhibition. The rate of major bleeding was higher in patients treated with GP IIb/IIIa inhibitors compared with placebo (2.4% vs 1.4%, P < .0001), but intracranial bleeding rates were similar (0.09% vs 0.06%, P ¼ .40). In contrast, medically managed patients have received no benefit from GP IIb/IIIa inhibition with abciximab. 89 
Therapeutic Implications
Despite the demonstrated benefits of current antiplatelet therapies, they are associated with a significant increase in bleeding risk. The increased risk can be attributed to the fact that these agents target platelet activation pathways critical for both protective hemostasis and pathological thrombosis. P 2 Y 12 ADP receptor antagonists increase bleeding risk particularly when used in combination with aspirin. 65, 67, 73 In CURE, clopidogrel plus aspirin increased the rate of major bleeding compared with aspirin alone (3.7% vs 2.7%, P ¼ .001). 67 Higher aspirin doses ( 100 mg, 101-199 mg, and !200 mg) increased the rate of major bleeding in both the dual antiplatelet therapy and aspirin-only groups. 90 Higher aspirin doses did not demonstrate greater efficacy versus low-dose aspirin for long-term prevention. 90 Thus, the optimal risk/benefit ratio depends on the dose of aspirin used. Moreover, bleeding risk may increase in proportion to the degree of P 2 Y 12 inhibition, as suggested by the results of TRITON. The greater efficacy of prasugrel versus clopidogrel was offset by significantly higher rates of TIMI major bleeding (2.4% vs 1.8%, P ¼ .03), including lifethreatening bleeding (1.4% vs 0.9%, P ¼ .01), and fatal bleeding (0.4% vs 0.1%, P ¼ .002). 73 Due to excess bleeding events, no net clinical benefit from prasugrel was observed in patients aged !75 years or those weighing <60 kg, and net harm was observed in patients with prior stroke or TIA. 73 In contrast, a net clinical benefit was observed in patients with diabetes 84 and those with STE MI, 83 without excess bleeding. Interindividual variability in response to antiplatelet drugs is another limitation of currently available agents. Variability in the degree of inhibition of platelet aggregation in response to aspirin, 91 clopidogrel, 92 and GP IIb/IIIa inhibitors 93 has been documented (see Kuliczkowski et al 94 for a recent review). Although standardized laboratory methodologies to assess variability and definitions of ''resistance'' have not been established, sufficient evidence suggests that suboptimal response to antiplatelet therapy is associated with poorer clinical outcomes. [91] [92] [93] The mechanisms responsible for interindividual variability in the response to antiplatelet agents are multifactorial and have only been partly elucidated. Several recent analyses suggest that genetic polymorphisms of the cytochrome P (CYP) 450 enzyme CYP2C19, which is required for the conversion of clopidogrel into an active metabolite, can significantly modulate individual response to clopidogrel and are important determinants of prognosis. [95] [96] [97] In patients with ACS or prior MI, increased risk of cardiovascular events was found in carriers of variant alleles. Recent guidance from a Working Group on Antiplatelet Resistance of the European Society of Cardiology suggests that interindividual variability can be overcome to some extent with higher doses of clopidogrel (ie, a 600-mg loading dose vs a 300-mg loading dose and a 150-mg/d maintenance dose vs a 75-mg/d 94 ). Routine monitoring of antiplatelet effects is currently not recommended. 94 Furthermore, current oral antiplatelet agents (aspirin and thienopyridines) exercise their inhibitory effect specifically on the platelet activation pathways stimulated by TxA 2 and ADP. 2 As discussed above, multiple pathways lead to platelet activation. Platelet activation may continue via other agonists (including thrombin) in patients receiving current standardof-care, dual antiplatelet therapy. This lack of comprehensive inhibition of platelet reactivity may possibly expose patients to risk for recurrent thrombotic events.
These considerations underscore the need for new agents that provide more comprehensive platelet inhibition and that do not interfere with hemostasis, which would translate clinically into greater protection against thrombotic events without the risk of incremental bleeding. Inhibition of the platelet thrombin receptor PAR-1 may provide more comprehensive inhibition of platelet-mediated thrombosis when used in combination with the current standard-of-care (aspirin and a P 2 Y 12 ADP receptor antagonist). Addition of a PAR-1 antagonist to the current standard-of-care may lead to greater reductions in adverse ischemic events without an increase in the bleeding risk. In a phase 2 trial in patients undergoing PCI, PAR-1 inhibition with the oral agent SCH 530348 was associated with a rate of TIMI major or minor bleeding that was similar to placebo and with a slight increase in non-TIMI bleeding. SCH 530348 also showed a nonsignificant reduction in death/ major cardiovascular events (Table 2) . 98 Two additional phase 2 trials in Japanese patients with NSTE ACS receiving SCH 530348 plus aspirin, ticlopidine, and heparin and in Japanese patients with prior stroke receiving SCH 530348 plus aspirin demonstrated no increased risk of TIMI major or minor bleeding with SCH 530348 versus placebo. 99, 100 Antiplatelet agents that inhibit PAR-1 activity may thus have a more favorable benefit-to-risk profile than current antiplatelet agents that target the TxA 2 and P 2 Y 12 ADP receptor pathways. Two phase 3 trials are further evaluating the safety and efficacy of SCH 530348 for the treatment and prevention of atherothrombotic disease. The TRACER trial is evaluating treatment with SCH 530348 versus placebo in addition to standard-of-care therapies in the prevention of ischemic events (composite of cardiovascular death, MI, stroke, recurrent ischemia with rehospitalization, and urgent coronary revascularization) in patients with NSTE ACS. 101 The TRA-2P-TIMI 50 trial is evaluating the safety and efficacy of SCH 530348 versus placebo in addition to standard therapies in the secondary prevention of ischemic events (composite of cardiovascular death, MI, stroke, and urgent coronary revascularization) in patients with prior MI or stroke or with peripheral arterial disease. 102 
Conclusion
Platelets can be activated by multiple agonists that each stimulates a distinct platelet activation pathway, leading to plateletmediated thrombosis. Current oral antiplatelet agents (aspirin and P 2 Y 12 ADP receptor antagonists) target the TxA 2 and ADP platelet activation pathways and have demonstrated wide benefit for the treatment of atherothrombotic disease. Despite these benefits, these agents are associated with important limitations. Key among these are bleeding risk, variability in platelet responsiveness, and residual risk of recurrent events. The hope is that developing novel therapeutic approaches that target platelet activation pathways not inhibited by current antiplatelet agents, such as PAR-1 for thrombin, will reduce further clinical events driven by platelet-mediated thrombosis without increasing bleeding risk. 
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